BioCentury | Aug 28, 2006
Finance

Ebb & Flow

...companies at PaineWebber, and before was a biotech analyst at Drexel Burnham Lambert and at Donaldson, Lufkin & Jenrette...
BioCentury | Jun 14, 2004
Company News

Angiotech management update

...as VP of business development, formerly a senior banker with Credit Suisse First Boston and Donaldson, Lufkin & Jenrette WIR...
BioCentury | Jun 17, 2002
Finance

Ebb & Flow

...head of U.S. biotech equity research at Lehman Brothers. Parker was a sellside analyst with Donaldson, Lufkin & Jenrette...
BioCentury | Jun 12, 2002
Financial News

Parker joins Lehman

...Parker had managed Immunex's oncology franchise following a stretch of sellside analyst work at both Donaldson, Lufkin & Jenrette...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech affiliate Pulsar International, will remain on KOSN's board. Wall Street tracks eMedsecurities hired former Donaldson, Lufkin & Jenrette...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech affiliate Pulsar International, will remain on KOSN's board. Wall Street tracks eMedsecurities hired former Donaldson, Lufkin & Jenrette...
BioCentury | Dec 4, 2000
Finance

Trailing indicator

...unit as chairman of its Global Health Care Partners division, which was a part of Donaldson, Lufkin & Jenrette...
BioCentury | Aug 21, 2000
Company News

Xcyte board of directors update

...Business: Autoimmune/Inflammation, Cancer, Infectious diseases Appointed: Robert Curry, general manager of The Sprout Group at Donaldson, Lufkin & Jenrette...
BioCentury | Aug 9, 2000
Financial News

AtheroGenics, Pharsight sell IPOs

...3.75 million shares at $12-$14. The offering, which has a 562,500-share overallotment, was underwritten by Donaldson, Lufkin & Jenrette...
BioCentury | Apr 17, 2000
Financial News

Pharsight files for IPO

...to raise up to $75 million in an IPO. The deal will be underwritten by Donaldson, Lufkin & Jenrette...
Items per page:
1 - 10 of 22
BioCentury | Aug 28, 2006
Finance

Ebb & Flow

...companies at PaineWebber, and before was a biotech analyst at Drexel Burnham Lambert and at Donaldson, Lufkin & Jenrette...
BioCentury | Jun 14, 2004
Company News

Angiotech management update

...as VP of business development, formerly a senior banker with Credit Suisse First Boston and Donaldson, Lufkin & Jenrette WIR...
BioCentury | Jun 17, 2002
Finance

Ebb & Flow

...head of U.S. biotech equity research at Lehman Brothers. Parker was a sellside analyst with Donaldson, Lufkin & Jenrette...
BioCentury | Jun 12, 2002
Financial News

Parker joins Lehman

...Parker had managed Immunex's oncology franchise following a stretch of sellside analyst work at both Donaldson, Lufkin & Jenrette...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech affiliate Pulsar International, will remain on KOSN's board. Wall Street tracks eMedsecurities hired former Donaldson, Lufkin & Jenrette...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech affiliate Pulsar International, will remain on KOSN's board. Wall Street tracks eMedsecurities hired former Donaldson, Lufkin & Jenrette...
BioCentury | Dec 4, 2000
Finance

Trailing indicator

...unit as chairman of its Global Health Care Partners division, which was a part of Donaldson, Lufkin & Jenrette...
BioCentury | Aug 21, 2000
Company News

Xcyte board of directors update

...Business: Autoimmune/Inflammation, Cancer, Infectious diseases Appointed: Robert Curry, general manager of The Sprout Group at Donaldson, Lufkin & Jenrette...
BioCentury | Aug 9, 2000
Financial News

AtheroGenics, Pharsight sell IPOs

...3.75 million shares at $12-$14. The offering, which has a 562,500-share overallotment, was underwritten by Donaldson, Lufkin & Jenrette...
BioCentury | Apr 17, 2000
Financial News

Pharsight files for IPO

...to raise up to $75 million in an IPO. The deal will be underwritten by Donaldson, Lufkin & Jenrette...
Items per page:
1 - 10 of 22